APP and aceruloplasminemia: This phenotype is accelerated when either APP or CP is genetically ablated in mice [2], [50] and may be a contributory pathogenic mechanism in human diseases associated with each protein, such as Alzheimer’s disease [51], [52], Parkinson’s disease [53] or aceruloplasminemia [54], [55].